The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...

Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...

The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

But two notable investigations — one still active — show the Federal Trade Commission (FTC ... PBMs (including related to the price of insulin), 45 it is the legislative arena that seems ...

According to her plan, new penalties enforced by the Federal Trade Commission and other agencies ... She also wants to limit the price of insulin payments to US$35 per month, increase subsidies ...

According to her plan, new penalties enforced by the Federal Trade Commission and other agencies would be imposed ... She also wants to limit the price of insulin payments to US$35 per month, increase ...

Vice President Kamala Harris’s economic proposals include a federal ban on price gouging on food, cost-lowering mechanisms for insulin and ... echoes a Federal Trade Commission report from ...